Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on Key Highlights of the Phase 3 ASPEN Trial
The trial evaluated zanubrutinib, a potent and selective BTK inhibitor, versus ibrutinib, a first generation BTK inhibitor, in patients with Waldenström macroglobulinemia.
In an interview with CancerNetwork®, Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, of the Peter MacCallum Cancer Centre, discussed the key highlights for patients from the phase 3 ASPEN trial.
Results from the randomized phase 3 ASPEN trial, presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Meeting, indicated that, though not statistically significant, zanubrutinib (Brukinsa) was associated with a higher complete response or very good partial response (CR+VGPR) rate and demonstrated clinically meaningful advances in safety and tolerability compared to ibrutinib (Imbruvica) in patients with Waldenström macroglobulinemia.
Transcription:
So, I think the key highlight for the patient is that we've got 2 drugs which are similar. One is zanubrutinib, it’s a more selective, in other words more targeted, version of ibrutinib, potentially with better side effects and will be competitive to drugs head to head. Indeed, we do see a difference in side effects, with zanubrutinib having less side effects and better tolerance than ibrutinib, which is great because it gives us extra options for treatment of Waldenströms.
Improving Disease Modification and Immune Responses in Myelofibrosis With Pelabresib
November 16th 2024David M. Swoboda, MD, and Andrew Kuykendall, MD, spoke about the current treatment strategies and potential advancements that may improve outcomes such as spleen volume reduction in the myelofibrosis field.
